Skip to main content
SpringerLink
Log in

Prodrugs of Peptides. 6. Bioreversible Derivatives of Thyrotropin-Releasing Hormone (TRH) with Increased Lipophilicity and Resistance to Cleavage by the TRH-Specific Serum Enzyme

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Bioreversible derivatization of TRH (pGlu–His–Pro–NH2) to protect the tripeptide against rapid enzymatic inactivation in the systemic circulation and to improve the lipophilicity of this highly hydrophilic peptide was performed by N-acylation of the imidazole group of the histidine residue with various chloroformates. Whereas TRH was rapidly hydrolyzed at its pGlu–His bond in human plasma by a TRH-specific pyroglutamyl aminopeptidase serum enzyme, the N-alkoxycarbonyl derivatives were resistant to cleavage by the enzyme. On the other hand, these derivatives are readily bioreversible as the parent TRH is formed quantitatively from the derivatives by spontaneous hydrolysis or by plasma esterase-catalyzed hydrolysis. In addition to protecting the parent TRH against rapid inactivation in the circulation and hence potentially prolonging the duration of action of TRH in vivo, the N-alkoxycarbonyl prodrug derivatives were much more lipophilic than TRH as assessed by octanol–buffer partitioning. This property may enhance prodrug penetration of the blood–brain barrier and various other biomembranes compared to the parent peptide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. G. Metcalf. Brain Res. Dev. 4:389–408 (1982).

    Google Scholar 

  2. I. M. D. Jackson. N. Engl. J. Med. 306:145–155 (1982).

    Google Scholar 

  3. E. C. Griffiths. Psychoneuroendocrinology 10:225–235 (1985).

    Google Scholar 

  4. E. C. Griffiths. Nature 322:212–213 (1986).

    Google Scholar 

  5. E. C. Griffiths. Clin. Sci. 73:449–457 (1987).

    Google Scholar 

  6. A. Horita, M. A. Carino, and H. Lai. Annu. Rev. Pharmacol. Toxicol. 26:311–332 (1986).

    Google Scholar 

  7. P. T. Loosen. Progr. Neuro-Psychopharmacol. Biol. Psychiat. 12:S87–S117 (1988).

    Google Scholar 

  8. G. Metcalf and I. M. D. Jackson (eds.). Ann. N.Y. Acad. Sci. 553:1–631 (1989).

  9. M. Hichens. Drug Metab. Rev. 14:77–98 (1983).

    Google Scholar 

  10. R. M. Bassiri and R. D. Utiger. J. Clin. Invest. 52:1616–1619 (1973).

    Google Scholar 

  11. J. E. Morley, T. J. Garvin, A. E. Pekary, R. D. Utiger, M. G. Nair, C. M. Baugh, and J. M. Hershman. J. Clin. Endocrinol. Metab. 48:377–380 (1979).

    Google Scholar 

  12. L. Duntas, F. S. Keck, and E. F. Pfeiffer. Dtsch. Med. Wschr. 113:1354–1357 (1988).

    Google Scholar 

  13. E. Iversen. J. Endocrinol. 118:511–516 (1988).

    Google Scholar 

  14. C. H. Emerson. Methods Enzymol. 168:365–371 (1989).

    Google Scholar 

  15. K. Bauer. Biochimie 70:69–74 (1988).

    Google Scholar 

  16. K. Bauer and P. Nowak. Eur. J. Biochem. 99:239–245 (1979).

    Google Scholar 

  17. W. L. Taylor and J. E. Dixon. J. Biol. Chem. 253:6934–6940 (1978).

    Google Scholar 

  18. J. Møss and H. Bundgaard. Pharm. Res. 7:751–755 (1990).

    Google Scholar 

  19. W. A. Banks and A. J. Kastin. Brain Res. Bull. 15:287–292 (1985).

    Google Scholar 

  20. Y. Nagai, S. Yokohama, and Y. Nagawa. J. Pharm. Dyn. 3:500–506 (1980).

    Google Scholar 

  21. H. Bundgaard. In S. S. Davis, L. Illum, and E. Tomlinson (eds.), Delivery Systems for Peptide Drugs, Plenum Press, New York, 1986, pp. 49–68.

    Google Scholar 

  22. H. Bundgaard and J. Møss. Biochem. Soc. Trans. 17:947–949 (1989).

    Google Scholar 

  23. H. Bundgaard and J. Møss. J. Pharm. Sci. 78:122–126 (1989).

    Google Scholar 

  24. F. C. Grønvald, N. L. Johansen, and B. F. Lundt. In E. Gross and F. Meinhofer (eds.), Peptides, Structure and Biological Function, Pro. 6th Am. Peptide Symp., 1979, pp. 309–312.

  25. F. C. Grønvald, B. F. Lundt, and N. L. Johansen. In K. Brunfeldt (ed.), Peptides. Proc. 16th Eur. Pept. Symp., 1980, Scriptor, Copenhagen, 1981, pp. 706–710.

    Google Scholar 

  26. E. Giralt, M.-D. Ludevid, and E. Pedroso. Bioorg. Chem. 14:405–416 (1986).

    Google Scholar 

  27. W. P. Jencks and J. Carriulo. J. Biol. Chem. 234:1272–1279 (1959).

    Google Scholar 

  28. W. B. Melchior, Jr., and D. Fahrney. Biochemistry 9:251–258 (1970).

    Google Scholar 

  29. U. Klixbüll and H. Bundgaard. Arch. Pharm. Chem. Sci. Ed. 11:101–110 (1983).

    Google Scholar 

  30. R. Wolfenden and W. P. Jencks. J. Am. Chem. Soc. 83:4390–4393 (1961).

    Google Scholar 

  31. G. Grant, N. Ling, J. Rivier, and W. Vale. Biochemistry 11:3070–3073 (1972).

    Google Scholar 

  32. S. Wilk. Ann. N.Y. Acad. Sci. 553:252–264 (1989).

    Google Scholar 

  33. M. Orlowski and A. Meister. In P. D. Boyer (ed.), The Enzymes, Academic Press, New York, 1971, Vol. IV, pp. 123–151.

    Google Scholar 

  34. G. N. Abraham and D. N. Podell. Mol. Cell. Biochem. 38:181–190 (1981).

    Google Scholar 

  35. T. C. Friedman and S. Wilk. J. Neurochem. 46:1231–1239 (1986).

    Google Scholar 

  36. S. Wilk and E. K. Wilk. Ann. N.Y. Acad. Sci. 553:556–558 (1989).

    Google Scholar 

  37. S. Wilk. Life Sci. 39:1487–1492 (1986).

    Google Scholar 

  38. K. Bauer, P. Nowak, and H. Kleinkauf. Eur. J. Biochem. 118:173–176 (1981).

    Google Scholar 

  39. R. Lanzara, M. Liebman, and S. Wilk. Ann. N.Y. Acad. Sci. 553:559–562 (1989).

    Google Scholar 

  40. J. C. Dvorak and R. D. Utiger. J. Clin. Endocrinol. Metab. 44:582–585 (1977).

    Google Scholar 

  41. C. Hansch and A. Leo. Substituent Constants for Correlation Analysis in Chemistry and Biology, John Wiley & Sons, New York, 1979.

    Google Scholar 

  42. D. A. Brent, J. J. Sabatka, D. J. Minick, and D. W. Henry. J. Med. Chem. 26:1014–1020 (1983).

    Google Scholar 

  43. T. L. Hakfenschied and E. Tomlinson. Int. J. Pharm. 16:225–239 (1983).

    Google Scholar 

  44. H. Bundgaard, E. Falch, C. Larsen, G. L. Mosher, and T. J. Mikkelson. J. Pharm. Sci. 75:775–783 (1986).

    Google Scholar 

  45. S. Yokohama, K. Yamashita, H. Toguchi, J. Takeuchi, and N. Kitamori. J. Pharm. Dyn. 7:101–111 (1984).

    Google Scholar 

  46. S. Yokohama, T. Yoshioka, K. Yamashita, and N. Kitamori. J. Pharm. Dyn. 7:445–451 (1984).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Royal Danish School of Pharmacy, Department of Pharmaceutical Chemistry, 2 Universitetsparken, DK-2100, Copenhagen, Denmark

    Hans Bundgaard & Judi Møss

Authors
  1. Hans Bundgaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Judi Møss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bundgaard, H., Møss, J. Prodrugs of Peptides. 6. Bioreversible Derivatives of Thyrotropin-Releasing Hormone (TRH) with Increased Lipophilicity and Resistance to Cleavage by the TRH-Specific Serum Enzyme. Pharm Res 7, 885–892 (1990). https://doi.org/10.1023/A:1015933504191

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015933504191

Search

Navigation